BridgeBio(US:BBIO)2026-02-24 22:32Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $154.2 million, consisting of $146 million from Attruby net product revenue, compared to $5.9 million for the same period last year, reflecting a significant increase of $148.3 million [32][33] - For the full year 2025, total revenues reached $502.1 million, up from $221.9 million in 2024, driven primarily by a $359.5 million increase in net product revenue from Attruby [33][34] - Operating costs for Q4 2025 were $293.7 million, compared to $231.9 million in the same period last year, with a notable increase in SG&A expenses [34][35] Business Line Data and Key Metrics Changes - Attruby's net product revenue for Q4 was $146 million, contributing to a total of $362.4 million for the year, with new patient starts reaching 7,804 [24][32] - The company reported a 35% quarter-over-quarter growth in net product revenue for Attruby, indicating strong commercial momentum [24][25] Market Data and Key Metrics Changes - Attruby achieved over 25% market share in the ATTR cardiomyopathy market as of December 31, 2025, with continued growth in unique patient prescriptions [18][24] - The company noted that the adoption of Attruby is accelerating, particularly in first-line patients, surpassing previous expectations [25][30] Company Strategy and Development Direction - The company is transitioning from a cash-consuming business to one that generates significant cash flows, with expectations of cash generation starting in late 2027 and becoming a cash generation engine by 2028 [8][9] - The focus remains on advancing three additional product candidates towards commercialization, with a strong emphasis on maintaining a best-in-class commercial engine for genetic diseases [10][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's fundamentals, despite recent stock volatility, and emphasized the intrinsic value of BridgeBio is increasing [11][12] - The company is actively evaluating options to ensure shareholder value is recognized, with over $1 billion in capital available to support its strategic initiatives [12][36] Other Important Information - The company has successfully completed three late-stage readouts, marking a transformative inflection point for BridgeBio [4][5] - Management highlighted the importance of clinical data in driving market share and emphasized the differentiated profile of Attruby compared to competitors [10][23] Q&A Session Summary Question: What drives Attruby's consistent growth despite competitors slowing down? - Management attributed growth to a strong field team, superior clinical data, and a disciplined focus on patient needs, leading to high adoption rates [39][41] Question: When will significant real-world data be available to establish clinical differentiation? - Management indicated that real-world evidence should be available by the end of the year, focusing on early impact and specific patient populations [51][52] Question: How does the company plan to use incremental free cash flow in the future? - The strategy includes reinvesting in R&D and potentially considering share buybacks or dividends if intrinsic value is not reflected in stock price [54][55] Question: Can you elaborate on launch readiness and expected regulatory catalysts? - The company plans to follow rigorous launch protocols similar to Attruby, with a focus on global launches and setting new standards of care [60][62] Question: What is the outlook on tafamidis IP and its impact on Attruby? - Management believes the tafamidis IP situation is a sideshow and does not impact Attruby's uptake, as the differentiated clinical data continues to drive momentum [78][83]